2023
DOI: 10.3390/ijms24108490
|View full text |Cite
|
Sign up to set email alerts
|

Extended Exposure Topotecan Significantly Improves Long-Term Drug Sensitivity by Decreasing Malignant Cell Heterogeneity and by Preventing Epithelial–Mesenchymal Transition

Abstract: Maximum tolerable dosing (MTD) of chemotherapeutics has long been the gold standard for aggressive malignancies. Recently, alternative dosing strategies have gained traction for their improved toxicity profiles and unique mechanisms of action, such as inhibition of angiogenesis and stimulation of immunity. In this article, we investigated whether extended exposure (EE) topotecan could improve long-term drug sensitivity by preventing drug resistance. To achieve significantly longer exposure times, we used a sph… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 50 publications
0
1
0
Order By: Relevance
“…To achieve combinatorial avenues, inhibitors of TCF with topo-active drugs have been explored as a new class of therapy [291,292]. Maximum tolerable dosing (MTD) of topotecan is suggested to cause enhanced EMT while extended exposure to topotecan induces increased long-term drug sensitivity by decreasing malignant heterogeneity and preventing EMT [293].…”
Section: Emt and Topo-active Drugsmentioning
confidence: 99%
“…To achieve combinatorial avenues, inhibitors of TCF with topo-active drugs have been explored as a new class of therapy [291,292]. Maximum tolerable dosing (MTD) of topotecan is suggested to cause enhanced EMT while extended exposure to topotecan induces increased long-term drug sensitivity by decreasing malignant heterogeneity and preventing EMT [293].…”
Section: Emt and Topo-active Drugsmentioning
confidence: 99%